北米の契約製造市場 – 業界動向と2030年までの予測

北米の契約製造市場の分析と洞察

北米の契約製造市場は、医薬品やパイプライン製品の技術進歩とコスト効率の向上による需要の高まり、研究開発への投資の増加などの要因によって牽引されており、市場の成長につながっています。現在、先進国と新興国全体で医療費が増加しており、メーカーが新しい革新的な製品を開発するための競争上の優位性が生まれると予想されています。

契約製造とは、企業と製造業者の間で、指定された期間内に企業のために一定数の部品または製品を製造する契約です。製造された商品は、企業のラベルまたはブランドで販売されます。これはプライベート ラベル製造と呼ばれます。国境を越えて行われる場合は、アウトソーシングとも呼ばれます。製造業者は、顧客が独自の設計、処方、仕様を提供しない限り、独自の設計、処方、仕様に基づいてサービスを提供します。製造業者は、競合企業であっても、契約した相手にこれらの製品を作成します。

契約製造市場の成長を牽引する主な要因の 1 つは、北米の医療機器および医薬品部門の需要の高まりです。いくつかの企業がより良い診断のために行っている継続的な臨床試験研究は、市場の拡大につながります。市場は、技術の進歩とコスト効率の向上にも影響されます。ただし、機密情報のリスクと厳格な規制は、予測期間中の北米の契約製造市場の抑制要因として機能する可能性があります。

一方、特許の期限切れやジェネリック医薬品の需要増加、医療インフラの費用増加、主要市場プレーヤーによる戦略的取り組みは、市場の成長の機会となります。しかし、知的財産リスクや独自の製造ユニットを設立する製薬会社の増加は、北米の契約製造市場に課題をもたらす可能性があります。

北米では、ポイントオブケア診断への傾向が高まっているため、契約製造の需要が増加するでしょう。さまざまな企業が、徐々に市場の成長につながる取り組みを行っています。

The North America contract manufacturing market is supportive and aims to reduce the manufacturing efforts of healthcare organizations. Data Bridge Market Research analyses that the North America contract manufacturing market will grow at a CAGR of 6.8% during the forecast period of 2023 to 2030.

North America Contract Manufacturing Dynamics

Market Definition

Contract manufacturing in international markets is used in situations when one company arranges for another company in a different country to manufacture its products; this is also known as international subcontracting or international outsourcing. The company provides the manufacturer with all the specifications, and, if applicable, also with the materials required for the production process. This type of contract sets out the requirements, which the manufacturer must meet concerning the quality of the products, certification, quantities, conditions and dates of delivery, etc. It also establishes guidelines for the inspection and testing of the products set forth by the company which contracts out the manufacture, or by its own clients. Furthermore, it also outlines modifications to orders, as well as guarantees and compensation in case of breach of contract. Since the process is essentially outsourcing production in foreign markets to a partner that privately brands the end product, there are a number of different companies and industries that can make use of this type of contract.

Drivers

• Cost-effectiveness for the manufacturing companies

The time-consuming manufacturing and ineffective production for several things and management are major burdens for public and private sector organizations. They are also essential for addressing complex challenges because a single organization is less effective in driving the change and sometimes required outcomes. The contract manufacturing companies will act as rising opportunities for both governmental and private sectors

The rising demand for contract manufacturing with improved accuracy and less time constraint pushes the key players for strategic initiatives. Owning contract manufacturing frees up the overhead charges required to invest in machinery, material, and another workforce, simplifying the production process and streamlining the supply chain by reducing the overall cost.

However, major market players are investing heavy capital in manufacturing to reach the demands of their end users. The contract manufacturing players are involved in making the strategies and implementing them by reducing the cost of production of these players. Contract manufacturing services to other firms also ensure efficiency and optimum usage of resources by using effective workforce, strategic intelligence, or working resources required in the production cycle.

• Rise of technological advancements in contract manufacturing

Introducing a new drug in the market promptly requires considerable investments in manufacturing due to the escalated demand in the pharmaceutical industry. Advanced technologies and skills are mandatory as some drugs have complex formulas and require specific equipment and techniques when mass-produced.

The usage of innovative technologies such as machine learning, big data, and artificial intelligence to develop pharmaceutical drugs or manufacture medical devices are being considered for rapid and quick manufacturing. These technical advancements also help in mass production and scalability in a short span of time.

However, pharmaceutical firms conventionally audit or supervise their contract manufacturing organization's production and delivery processes to monitor the manufacturing process using real-time remote tracing.

Opportunities

• Growing expenses on the development of healthcare infrastructure

Infrastructure is a key pillar supporting the fundamental aim of promoting improved standards of care and well-being for all patients, together with a good healthcare system experience. In parallel, the healthcare system and staff must support effective health promotion, prevention, and self-care of the whole population. Infrastructure must integrate the hospital, as the center for acute and inpatient care, into the broader healthcare system and should facilitate the seven domains of quality patient experience, effectiveness, efficiency, timeliness, safety, equity, and sustainability. Infrastructure includes the built environment and supporting elements: equipment, access, information technology (IT), systems and processes, sustainability initiatives, and staff.

However, the growing expenses on the development of healthcare infrastructure are propelling the growth of the North America contract manufacturing market in the forecast period.

Restraints/Challenges

• Increase in the Number of Pharmaceutical Companies Set Up Their Manufacturing Sites

Most pharmaceutical companies are building manufacturing sites to produce pharmaceutical products to reduce costs. Manufacturers are more focused on introducing advanced technologies and the digitalization process. The Pharma industry also faces disruptions due to new business models and a more focused population on personalized medicines and treatments. Hence, the demand for personalized care is high. Occupational profiles are also changing: some jobs are disappearing due to automation while entirely new jobs are emerging.

Hence, the increasing number of pharmaceutical companies setting up their manufacturing units may challenge the growth of the North America contract manufacturing market in the forecast period.

Recent Developments

• In October 2021, Boehringer Ingelheim International gmbh., had inaugurated its state-of-the-art biopharmaceutical production facility Large Scale Cell Culture (LSCC) in Vienna, Austria, with an investment volume of more than 700 million EUR, which is the single largest investment in the company's history
• In March 2023, Evonik Industries AG has announced that it is opening a new GMP facility to manufacture lipids for advanced, pharmaceutical drug delivery applications. The lipid launch facility is located at the company’s site in Hanau, Germany and provides customers with quantities of lipids as needed for clinical and small-scale commercial manufacturing

North America Contract Manufacturing Market Segmentation

The North America contract manufacturing market is categorized into three notable segments based on product, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Product

• Medical Device Manufacturing
• Pharmaceutical Products Manufacturing

On the basis of product, the North America contract manufacturing market is segmented into medical device manufacturing and pharmaceutical products manufacturing.

End User

• Pharmaceutical Companies
• Biotechnology Companies
• Biopharma Companies
• Medical Device Companies
• Original Equipment Manufacturer
• Research Institutes

On the basis of end user, the North America contract manufacturing market is segmented into original equipment manufacturer, medical device companies, pharmaceutical companies, biotechnology companies, biopharma companies, and research institutes.

Distribution Channel

• Retail Sales
• Direct Tender
• Others

On the basis of distribution channel, the North America contract manufacturing market is segmented into direct tenders, retail sales, and others.

North America Contract Manufacturing Market Regional Analysis/Insights

The North America contract manufacturing market is analyzed, and market size insights and trends are provided by product, end user, and distribution channel as referenced above.

The countries covered in the contract manufacturing report are U.S., Canada, Mexico.

発展途上地域での技術進歩の進展により、米国が優位に立つことが予想されます。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、北米ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。

競争環境と北米の契約製造市場シェア分析

北米の契約製造市場の競争状況では、競合他社の詳細が提供されます。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、北米でのプレゼンス、生産拠点と施設、生産能力、会社の長所と短所、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、北米の契約製造市場における会社の焦点にのみ関連しています。

この市場のプレーヤーとしては、Aenova Group、Thermo Fisher Scientific Inc.、EVONIK INDUSTRIES AG、Lonza、Boehringer Ingelheim Biopharmaceuticals GmbH、Catalent, Inc などがあります。

SKU-69920